The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: Potential steroid-sparing role for DHEA

Cytokine

Volumn 36, Issue 1-2, 2006, Pages 57-68

  Harding, G ^a   Mak, Y T ^a   Evans, B ^b   Cheung, J ^a   MacDonald, D ^a   Hampson, G ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cytokines; Dehydroepiandrosterone; Osteoblasts; Osteoprotegerin; RANKL

Indexed keywords

ANDROSTENEDIONE; COMPLEMENTARY DNA; CYTOKINE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 5; GAMMA INTERFERON; INSULIN RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; NOTCH2 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PRASTERONE; PROTEINASE ACTIVATED RECEPTOR 1; SOMATOMEDIN BINDING PROTEIN 3; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE REMODELING; CATABOLISM; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REAL TIME ECHOGRAPHY; UPREGULATION;

ANDROSTENEDIONE; CELL LINE; CYTOKINES; DEHYDROEPIANDROSTERONE; DEXAMETHASONE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, CYTOKINE; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846005178     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.10.012     Document Type: Article

References (42)

1. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., and Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 (2000) 993-1000
2. Schwarz K.E. Autoimmunity, dehydroepiandrosterone (DHEA) and stress. J Adolescent Health 30S (2002) 37-40
3. Petri M.A., Lahita R.G., Van Vollenhoven R.F., Merill J.T., Schiff M., Ginzler E.M., Strand V., Kunz A., Gorelick K.J., and Schwarz K.E. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 46 7 (2002) 1820-1829
4. Canalis E., and Delany A.M. Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 966 (2002) 73-81
5. Dempster D. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 13 (1998) 137-141
6. Kasperk C.H., Wakey G.K., Hierl T., and Ziegler R. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 12 3 (1997) 464-471
7. Labrie F., Diamond P., Cusan L., Gomez J.L., Belanger A., and Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in post-menopausal women. J Clin Endo Metab 82 10 (1997) 3498-3505
8. Martel C., Sourla A., Pelletier G., Labrie C., Formier M., Picard, et al. Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J Endocrinol 157 (1998) 433-442
9. Hofbauer L.C., and Khosla S. Androgen effects on bone metabolism: recent progress and controversies. Eur J Endocrinol 140 (1999) 271-286
10. Straub R.H., Konecna L., Hrach S., Rothe R., Krentz M., Scholmerich J., et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulphate are negatively correlated with serum interleukin-6 (IL-6) and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenenescence and immunosenescence. J Clin Endocrinol Metab 83 (1998) 2012-2017
11. Derksen R.H.M.W. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. Semin Arthritis Rheum 27 (1998) 335-347
12. Arron J.R., and Choi Y. Bone versus immune system. Nature 408 (2000) 535-536
13. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., Takaoka A., Yokochi T., et al. T-cell mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature 408 (2000) 600-605
14. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boylew W.J., and Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15 (2000) 2-12
15. Hofbauer L.C., Gori F., Riggs L., Lacey D.L., Dunstan C.R., Spelsberg T.C., and Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4382-4389
16. Ogston N., Harrison A.J., Cheung H.F.J., Ashton B.A., and Hampson G. Dexamethasone and retinoic acid differentially regulate growth and differentiation in an immortalized human clonal bone marrow cell line with osteoblastic characteristics. Steroids 67 (2002) 895-906
17. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
18. Sivagurunathan S., Muir M.M., Brennan T.C., Seale J.P., and Mason R.S. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20 (2004) 390-398
19. Egbali-Fatoureli G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., and Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early post-menopausal women. J Clin Invest 111 (2003) 1221-1230
20. Bashir A., Mak Y.T., Sankaralingam S., Cheumg J., Mc Gowan N.W.A., Grigoriadis A.E., Fogelman I., and Hampson G. Changes in RANKL/OPG/RANK gene expresson in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70 (2005) 847-855
21. Cheung J., Mak Y.T., Papaioannou S., Evans B.A.J., Fogelman I., and Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene. J Endocrinol 177 (2003) 423-433
22. Chen F., Knecht K., Birzin E., Fisher J., Wilkinson H., Mojena M., Moreno C.T., Schmidt A., Harada S., Freedman L.P., and Reszka A.A. Direct agonist/antagonist functions of dehydroepiandrosterone (DHEA). Endocrinology (2005) 30 on line
23. Hofbauer L.C., Khosla S., Dunstan C.R., Lacet D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999) 4367-4370
24. Khosla S., Atkinson E.J., Dunstan C.R., and O'Fallon W.M. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87 (2002) 1550-1554
25. Hofbauer L.C., Schoppet M., Schuller P., Viereck V., and Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol 60 (2004) 214-219
26. Hofbauer L.C., Hicok K.C., Chen D., and Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol 147 2 (2002) 269-273
27. Pacifici R. Estrogens, cytokines and pathogenesis of post-menopausal osteoporosis. J Bone Miner Res 11 (1996) 1043-1051
28. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., and Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106 10 (2000) 1229-1237
29. Cenci S., Toraldo G., Weitzmann M.W., Roggia C., Gao Y., Qian W.P., et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II trans-activator. Proc Natl Acad Sci 100 (2003) 10405-10410
30. Schulak J.A. Steroid-immunosuppression in kidney transplantation: a passing era. J Surg Res 117 (2004) 154-162
31. Canalis E. Machanisms of glucocorticoid-action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81 (1996) 3441-3447
32. Tezuka K., Yasuda M., Watanabe N., Morinura N., Kuroda K., Miyatani S., and Hozumi N. Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res 17 2 (2002) 231-239
33. Pun K.K., Lau P., and Ho P.W. The characterization, regulation and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res 4 6 (1989) 853-862
34. Song S.J., Pagel C.N., Pike R.N., and Mackie E.J. Studies on the receptors mediating responses of osteoblasts to thrombin. Int J Biochem Cell Biol 37 1 (2005) 206-213
35. Murray J.C., Heng Y.M., Symonds P., Rice K., Ward W., Huggins M., Todd I., and Robins R.A. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. J Leukoc Biol 75 95 (2004) 772-776
36. Blanquaert F., Pereira R.C., and Canalis E. Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts. Am J Physiol Endocrinol 278 (2000) 509-515
37. Borst J., Hendricks J., and Xiao Y. CD 27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17 (2005) 275-281
38. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hutner L., Heuman D., Mannel D., Bucala R., and Glauser M.P. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6 (2000) 164-170
39. Hoi A.Y., Morand E.F., and Leech M. Is macrophage inhibitory factor a therapeutic target in systemic lupus erythematosus?. Immunol Cell Biol 81 (2003) 367-373
40. Harada S., Nagy J.A., Sullivan K.A., et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 93 (1994) 2490-2496
41. Street J., Bao M., De Guzman L., Bunting S., Peale F.V., Ferrara N., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci 99 (2002) 9656-9661
42. Solerte S.B., Ferrari E., Cuzzoni G., Locatelli E., Giustina A., Zamboni M., Schifoni N., et al. Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate. Dement Geriatr Cogn Disord 19 1 (2005) 1-10